Supernus Pharmaceuticals SUPN Royalty, licensing, and other revenues — Total revenues

Other product segments

Similar metrics at other companies

ARDXLicensing revenue — Total revenues

$96K+380%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

NTRALicensing and other revenues — Total revenues

$4.82M+122%

BMRNRoyalty and other revenues — Total revenues

$5.32M-57.2%

CURILicensing — Total revenues

$6.02M+11.2%

HRBRoyalty, product and other revenues — Total revenues

$171.78M-3.3%

FAQ

What is Supernus Pharmaceuticals's royalty, licensing, and other revenues — total revenues?

Supernus Pharmaceuticals (SUPN) reported royalty, licensing, and other revenues — total revenues of $29.31M in Q1 2026.

How has Supernus Pharmaceuticals's royalty, licensing, and other revenues — total revenues changed year-over-year?

Supernus Pharmaceuticals's royalty, licensing, and other revenues — total revenues increased by 274.0% year-over-year, from $7.84M to $29.31M.

What is the long-term trend for Supernus Pharmaceuticals's royalty, licensing, and other revenues — total revenues?

Over 3 years (2022 to 2025), Supernus Pharmaceuticals's royalty, licensing, and other revenues — total revenues has grown at a 30.3% compound annual growth rate (CAGR), from $17.81M to $39.42M.

What does royalty, licensing, and other revenues — total revenues mean?

This metric represents the total revenue generated from intellectual property licensing agreements, royalty payments from partners, and other non-core service arrangements. It reflects the company's ability to monetize its proprietary technology and drug portfolio through third-party commercialization efforts rather than direct product sales. Monitoring this stream provides insight into the scalability of the company's research and development pipeline and the strength of its external partnership ecosystem.